| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
5-Hydroxyuridine targets DNA and RNA, where it acts as a modified nucleoside. As a product of oxidative damage, it is recognized by DNA repair enzymes such as single-strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1). In cancer research, it acts as a purine nucleoside analog that inhibits DNA synthesis and induces apoptosis.
|
|---|---|
| ln Vitro |
5-Hydroxyuridine demonstrates in vitro antitumor activity as a purine nucleoside analog. It inhibits DNA synthesis and induces apoptosis in cancer cells. The compound's mutagenic potential and role in oxidative DNA damage make it a valuable tool for studying DNA damage and repair mechanisms.
|
| ln Vivo |
In vivo activity of 5-hydroxyuridine has not been extensively documented. Its role as a product of oxidative damage suggests potential for studying oxidative stress-related diseases. Its antitumor activity suggests potential for in vivo efficacy in cancer models, but further studies are needed.
|
| Enzyme Assay |
In vitro enzyme assays for 5-hydroxyuridine involve measuring its recognition and excision by DNA repair enzymes such as SMUG1. The compound can be used as a substrate in glycosylase activity assays to measure the removal of oxidized bases from DNA.
|
| Cell Assay |
In vitro cellular assays for 5-hydroxyuridine involve treating cells with the compound and measuring DNA damage, mutagenesis, or cell viability. The compound's effects on DNA synthesis can be assessed by measuring the incorporation of radiolabeled nucleotides. Its mutagenic potential can be evaluated using mutation reporter assays.
|
| Animal Protocol |
In vivo animal experiments for 5-hydroxyuridine are not extensively documented. If used in animal models, typical protocols would involve administering the compound to study oxidative DNA damage and its biological consequences.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5-hydroxyuridine are limited. The compound has a molecular weight of 244.20 and a molecular formula of C9H12N2O6. Its absorption, distribution, metabolism, and excretion properties have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for 5-hydroxyuridine indicate that it is a product of oxidative DNA damage with mutagenic potential. The compound should be handled with appropriate safety precautions. It is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
5-Hydroxyuridine is a type of uridine compound in which the hydrogen atom at the 5-position of the uracil ring is replaced by a hydroxyl group. It is both a uridine compound and an organic hydroxyl compound.
5-Hydroxyuridine (OHUrd) (CAS#: 957-77-7) has the molecular formula C9H12N2O6 and a molecular weight of 244.20. It is a modified nucleoside and product of oxidative DNA damage with mutagenic potential. The compound is used in research on DNA damage, repair, and cancer. It is for research use only. |
| Molecular Formula |
C9H12N2O7
|
|---|---|
| Molecular Weight |
260.20
|
| Exact Mass |
260.064
|
| CAS # |
957-77-7
|
| PubChem CID |
94196
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Index of Refraction |
1.698
|
| LogP |
-1.51
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
410
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O
|
| InChi Key |
QXDXBKZJFLRLCM-UAKXSSHOSA-N
|
| InChi Code |
InChI=1S/C9H12N2O7/c12-2-4-5(14)6(15)8(18-4)11-1-3(13)7(16)10-9(11)17/h1,4-6,8,12-15H,2H2,(H,10,16,17)/t4-,5-,6-,8-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxypyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (480.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8432 mL | 19.2160 mL | 38.4320 mL | |
| 5 mM | 0.7686 mL | 3.8432 mL | 7.6864 mL | |
| 10 mM | 0.3843 mL | 1.9216 mL | 3.8432 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
